公开(公告)号：HK1057499A1

公开(公告)日：2004-04-08

申请号：HK04100307

申请日：2004-01-15

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K20060101 ,  A61K45/00 ,  A61P20060101 ,  A61P1/00 ,  A61P3/04 ,  C12Q20060101 ,  C12Q1/02 ,  C12Q1/527 ,  G01N20060101 ,  G01N33/15

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：AR028730A1

公开(公告)日：2003-05-21

申请号：ARP010102883

申请日：2001-06-15

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  FREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15 ,  A61K31/7004

Abstract: Un procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxis de la obesidad, determinando la capacidad de los compuestos a investigar de inhibir la lipogénesis de nuevo en mamíferos y/o seres humanos. Utilizacion de compuestos que poseen la capacidad de inhibir la lipogénesis de nuevo en mamíferos y que están esencialmente exentos de efectos dirigidos al SNC, para la preparacion de medicamentos para el tratamiento y/o profilaxis de la obesidad.

公开(公告)号：NO20024351A

公开(公告)日：2003-03-14

申请号：NO20024351

申请日：2002-09-12

Applicant: SOLVAY PHARM GMBH

Inventor： JASSERAND DANIEL ,  ANTEL JOCHEN ,  SANN HOLGER ,  REICHE DANIA ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  BRUECKNER REINHARD ,  EECKHOUT CHRISTIAN

IPC: C07D295/12 ,  A61K31/341 ,  A61K31/381 ,  A61K31/496 ,  A61P1/00 ,  A61P29/00 ,  A61P43/00 ,  C07D209/08 ,  C07D295/08 ,  C07D295/084 ,  C07D295/092 ,  C07D307/52 ,  C07D333/20 ,  C07D407/04 ,  C07D407/06 ,  C07D409/06 ,  C07D295/00 ,  A61K31/495

CPC classification number: C07D295/092 ,  C07D307/52 ,  C07D333/20 ,  C07D407/04

公开(公告)号：CA2416647A1

公开(公告)日：2003-01-20

申请号：CA2416647

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： PREUSCHOFF ULF ,  ANTEL JOCHEN ,  HEBEBRAND JOHANNES ,  SANN HOLGER ,  DAVID SAMUEL ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15

Abstract: The invention relates to a method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity, whereby the ability of the examined compounds to inhibit de novo lipogenase in mammals and/or humans is determined. Also disclosed is the use of compounds which are capable of inhibiting de novo lipogenase in mammals in the production of medicaments fo r the treatment and/or phophylaxis of obesity.

公开(公告)号：DZ3393A1

公开(公告)日：2002-01-31

申请号：DZ013393

申请日：2001-07-12

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  FREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：DE10035227A1

公开(公告)日：2002-01-31

申请号：DE10035227

申请日：2000-07-20

Applicant: SOLVAY PHARM GMBH

Inventor： HEBEBRAND JOHANNES ,  ANTEL JOCHEN ,  PREUSCHOFF ULF ,  DAVID SAMUEL ,  SANN HOLGER ,  WESKE MICHAEL

IPC: G01N33/50 ,  A61K45/00 ,  A61P1/00 ,  A61P3/04 ,  C12Q1/02 ,  C12Q1/527 ,  G01N33/15 ,  A61K31/7004

Abstract: Compounds for the treatment and/or prevention of obesity are selected on the basis of their capability to inhibit de novo lipogenesis in mammals. An independent claim is also included for the use of compounds which are capable of inhibiting de novo lipogenesis in mammals and which have no anticonvulsant activity for the production of a medicament for the treatment and/or prevention of obesity. - ACTIVITY : Anorectic. - MECHANISM OF ACTION : Lipogenesis inhibitor; Carboanhydrase inhibitor. No biological data given.

公开(公告)号：HU9801888A2

公开(公告)日：1999-05-28

申请号：HU9801888

申请日：1998-08-17

Applicant: SOLVAY PHARM GMBH

Inventor： ANTEL JOCHEN ,  BIELENBERG GERHARD-WILHELM ,  BRUECKNER REINHARD ,  DAVID SAMUEL ,  EECKHOUT CHRISTIAN ,  PECK MICHAEL ,  ZIEGLER DIETER

IPC: A61K31/55 ,  A61P1/00 ,  A61P43/00 ,  C07D243/08

Abstract: 1-Benzoyl-4-aminoacyl-7-phenyl-1,4-diazepine derivatives (I) are new. Also new are four classes of intermediates. 1,4-Diazepine derivatives of formula (I) and their acid addition salts are new. Ph1 = phenyl substituted by R2 and R3; Ph2 = phenyl substituted by R4 and R5; Ph3 = 3-(R6)-5-(R7)-phenyl; R1 = H or alkyl; R2-R5 = H, alkyl, alkoxy, halo or CF3; or R2+R3 or R4+R5 on adjacent C = 1-2C alkylenedioxy; R6,R7 = alkyl, halo or CF3; A = (CH2)n or NH(CH2)m; n = 1-3; m = 2 or 3; and B = 1-3C alkylene chain (optionally substituted by alkyl).

公开(公告)号：CZ9802672A3

公开(公告)日：1999-03-17

申请号：CZ267298

申请日：1998-08-21

Applicant: SOLVAY PHARM GMBH

Inventor： DAVID SAMUEL ,  ANTEL JOCHEN ,  BRUCKNER REINHARD ,  ZIEGLER DIETER ,  EECKHOUT CHRISTIAN ,  BIELENBERG GERHARD-WILHELM ,  PECK MICHAEL

IPC: A61K31/55 ,  A61P1/00 ,  A61P43/00 ,  C07D243/08

CPC classification number: C07D243/08 ,  Y02P20/55

公开(公告)号：CZ267298A3

公开(公告)日：1999-03-17

申请号：CZ267298

申请日：1998-08-21

Applicant: SOLVAY PHARM GMBH

Inventor： DAVID SAMUEL ,  ANTEL JOCHEN ,  BRUCKNER REINHARD ,  ZIEGLER DIETER ,  EECKHOUT CHRISTIAN ,  BIELENBERG GERHARD-WILHELM ,  PECK MICHAEL

IPC: A61K31/55 ,  A61P1/00 ,  A61P43/00 ,  C07D243/08

Abstract: 1-Benzoyl-4-aminoacyl-7-phenyl-1,4-diazepine derivatives (I) are new. Also new are four classes of intermediates. 1,4-Diazepine derivatives of formula (I) and their acid addition salts are new. Ph1 = phenyl substituted by R2 and R3; Ph2 = phenyl substituted by R4 and R5; Ph3 = 3-(R6)-5-(R7)-phenyl; R1 = H or alkyl; R2-R5 = H, alkyl, alkoxy, halo or CF3; or R2+R3 or R4+R5 on adjacent C = 1-2C alkylenedioxy; R6,R7 = alkyl, halo or CF3; A = (CH2)n or NH(CH2)m; n = 1-3; m = 2 or 3; and B = 1-3C alkylene chain (optionally substituted by alkyl).

公开(公告)号：AU8189998A

公开(公告)日：1999-03-11

申请号：AU8189998

申请日：1998-08-26

Applicant: SOLVAY PHARM GMBH

Inventor： JASSERAND DANIEL ,  DAVID SAMUEL ,  ANTEL JOCHEN ,  BRUCKNER REINHARD ,  EECKHOUT CHRISTIAN ,  BIELENBERG GERHARD-WILHELM

IPC: C07D403/06 ,  A61K31/495 ,  A61K31/496 ,  A61P1/00 ,  A61P29/00 ,  A61P43/00 ,  C07D209/00 ,  C07D209/14 ,  C07D241/00

Abstract: Compounds of Formula I wherein R1 is hydrogen or lower alkyl, R2 is hydrogen or halogen and R3 is hydrogen or lower alkoxy, and their pharmacologically acceptable acid addition salts and pharmaceutical compositions containing these compounds and also processes for the preparation of these compounds. Pharmaceutical composition containing these compounds are suitable, for example, for treating functional and inflammatory disorders of the gastrointestinal tract.